Tyloxapol

SKU: orb1310738

Description

Tyloxapol is a nonionic polymeric surfactant used in research. It is widely employed to establish hyperlipidemia models in animal studies and has applications in vitro for stabilizing emulsions and dispersions in biochemical assays.

Research Area

Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 25301-02-4
• Target: LPL Receptor,NF-κB
• Solubility: H2O:25 mg/mL;DMSO:38 mg/mL

Bioactivity

• In Vivo:
  A single intravenous injection of tyloxapol at dose of 400 mg/kg body weight shows three distinctive phases, sharp linear increment, slow linear increment and slow decrement of plasma lipids toward the basal levels. The treatment of tyloxapol enhannces the pulmonary absorption of rh-insulin and increases the absorption of inhaled insulin in diabetic rats. It might significantly increase the hypoglycemic effect of intratracheally administered insulin in diabetic rats but does not change the LDH activity.
  Read more...
• In Vitro:
  Tyloxapol is generally regarded as a safe stabilizer. In some studies, it is reported to causes cytotoxicity in epithelial and red blood cells, induces lysis of human Jurkat T-lymphoblasts and the apoptosis in RAW 264.7 murine macrophage-like cells and NIH/3T3 mouse fibroblast cells. These indications of cytotoxicity, however, do not reflect the in vivo use of Tyloxapol, since it is rarely used alone in clinical applications.
  Read more...
• Cell Research:
  HEK293 cells growing at 40% confluency are exposed to different test dispersions of SLP or their individual components for 48 h and observed the alterations in cellular morphology.(Only for Reference)
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

NFκB, NF-κB, NF-kB, NFkB, inhibit, LPL Receptor, LPLReceptor, LPL, Inhibitor, Tyloxapol, Triton WR 1339, Triton WR1339, Triton WR-1339

Compound Identifiers

PubChem CID

5610